Skip to main content

HLTH, Evercore ISI and the Digital Therapeutics Alliance Host DTx Leaders

Panels focus on sector trends, funding and revenue at HLTH in Las Vegas, Oct. 8, 2023

Evercore (NYSE: EVR), the Digital Therapeutics Alliance, and HLTH, a platform bringing together the health ecosystem, will co-host a dedicated program on digital therapeutics at HLTH 2023 in Las Vegas, Oct. 8-11. The event marks Evercore’s fifth consecutive year hosting at HLTH and second year collaborating with thought leaders from DTA to raise awareness for this promising and fast-growing vertical of healthcare.

The program, Digital Therapeutics: From Funding to Revenue Generation … A Strategy for Today’s Game is scheduled Sunday, Oct. 8, 9:30-11 a.m. PST at the Las Vegas Convention Center. Two panels of leading industry executives will focus on the current funding environment, as well as the evolution of payment and revenue opportunities across domestic and international channels.

“Digital therapeutics is well into its evolution of patient care, and despite some market volatility, the sector continues to be resilient and progress forward. Our panels will delve into prevailing investment trends in the sector as well as opportunities to maximize revenue for solutions that show promise clinically and economically,” said Elizabeth Anderson, Evercore ISI’s Healthcare Technology & Distribution analyst. “We are excited to partner again this year with HLTH and DTA to provide our insights on this rapidly evolving market.”

Jessica Hauflaire, COO of DTA, said, “Our partnership with Evercore at this year's HLTH conference allows us to share timely insights from the digital therapeutics industry with the wider healthcare ecosystem. We are thankful to have a space for both veterans and newcomers to talk about overcoming hurdles to healthcare innovation and improving the lives of patients and their families.”

“With markets changing significantly for digital therapeutics innovation over the past year, it’s more important than ever for companies to have informed funding and reimbursement strategies,” said HLTH President Rich Scarfo. “Our continued partnership with Evercore and the Digital Therapeutics Alliance delivers the type of expert guidance we want for HLTH attendees.”

For more information, visit www.hlth.com/2023event/partner-programs/evercore-isi.

About Evercore

Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings and capital structure. Evercore also assists clients in raising public and private capital, delivers equity research and equity sales and agency trading execution, and provides wealth and investment management services to high-net-worth and institutional investors. Founded in 1995, the firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in the Americas, Europe, the Middle East and Asia. For more information, please visit www.evercore.com.

About HLTH

HLTH (pronounced “health”) is the leading platform bringing together the entire health ecosystem, focused on health innovation and transformation. From unparalleled events with industry-leading speakers to inspirational digital content and mission-driven initiatives, HLTH creates a unique marketplace for the health community leading the dialogue and development of a new health ecosystem.

Contacts

Evercore Business: Elizabeth Anderson

Healthcare Technology & Distribution Analyst, Evercore ISI.

(212) 446-5632

Media: Jamie Easton

Head of Communications & External Affairs

Communications@Evercore.com



Or



S
hree Dhond / Zach Kouwe

Dukas Linden Public Relations

Evercore@DLPR.com

(646) 722-6531

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.